These are reviewed studies whose abstracts concern Squamous Cervical Carcinoma. Each describes only what that study reported. This is not a claim by OncoForge that any compound helps or harms Squamous Cervical Carcinoma. Most are early lab, animal, or small human studies, and findings often conflict.
3 studies2 human⚠ Conflicting evidence
Tracking 3 published studies of Squamous Cervical Carcinoma: 2 in humans, 1 reviews/other.
Reported direction across studies: 1 positive, 1 mixed, 1 inconclusive.
Findings conflict — both supportive and negative/mixed results exist (see below). Human evidence is limited.
These counts summarize what the studies reported; they are not a measure of whether anything works for Squamous Cervical Carcinoma.
Human · observationalReported positiveLimited evidenceTier 3 · early humann = 10
BMC cancer · Dec 2024 · retrospective cohort
Trastuzumab-deruxtecan-t-dxdTrastuzumab-deruxtecanendometrial neoplasmsovarian neoplasmscervical neoplasmsuterine carcinosarcomauterine leiomyosarcomauterine serous carcinomaovarian carcinosarcomahigh-grade serous ovarian carcinomamucinous ovarian carcinomasquamous cervical carcinoma This retrospective single-center study identified 10 patients with HER2-expressing (IHC 2+/3+) recurrent or metastatic gynecological cancers who received trastuzumab deruxtecan (5.4 mg/kg IV every 3 weeks). The cohort had a median progression-free survival of 5.4 months (95% CI 0.8-9.8). Five patients had a partial response, one had stable disease at 12 weeks, and four had disease progression at initial assessment. Clinical benefit was observed mainly in tumors with HER2 IHC 3+.
Reported effects: median PFS 5.4 mo [0.8–9.8], n=10 · partial responses 5, n=10 · +2 more
Key findings
- 10 patients with recurrent/metastatic HER2-expressing gynecological malignancies were treated with T-DXd.
- Histologies included uterine neoplasms (n=5), cervical squamous carcinoma (n=1) and ovarian cancers (n=4).
- Median age was 65.4 years (25th-75th percentile, 58.1-75.2 years).
- HER2 by IHC: 5 patients were 3+ and 5 patients were 2+.
- Median number of prior therapy lines was 4 (range 2-6); 2 uterine serous carcinoma patients were pretreated with trastuzumab and 4 patients had prior immunotherapy.
- Dose: T-DXd 5.4 mg/kg IV every 3 weeks until progression/toxicity.
- Median progression-free survival (PFS) in the cohort was 5.4 months (95% CI 0.8-9.8 months).
- Responses: 5 patients had partial response (including 2 previously treated with trastuzumab), 1 patient had stable disease at 12 weeks, 4 patients had disease progression at initial assessment.
- Most patients who derived clinical benefit had HER2 IHC 3+ expression.
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract; Potential selection and reporting bias inherent to retrospective series.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
ReviewInconclusiveLimited evidenceTier 3 · early human
Japanese journal of radiology · Apr 2024 · narrative review
squamous cervical carcinoma (locally advanced, M0)
This narrative review discusses diagnostic and clinical management advances for locally advanced squamous cervical carcinoma (M0), including PET-MRI to improve staging, new radiation technologies to deliver higher doses while lowering toxicities, evolving surgical concepts, and the growing potential role of targeted therapies and immunotherapy. It summarizes emerging options in the precision radiotherapy era but does not present new experimental data.
Key findings
- PET-MRI can improve clinical staging accuracy for squamous cervical carcinoma.
- New radiation therapy technologies permit delivery of higher doses while lowering toxicities.
- New surgical concepts could contribute to overall management in this setting.
- Targeted therapies and immunotherapy are anticipated to have an increasing role in the management of locally advanced SCC.
Limitations: Narrative review (not a systematic review) with potential for subjective selection and interpretation of literature.; No original experimental or quantitative data reported in the abstract.; Abstract does not specify particular targeted agents, immunotherapies, or clinical trial results..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
Meta-analysisMixed resultsLimited evidenceTier 4 · clinicaln = 210
Gynecologic oncology · May 2004 · literature review / meta-analysis (MEDLINE, EMBASE, CINAHL search 1966-2003)
squamous cervical carcinoma (FIGO stage IA2)
This review searched MEDLINE, EMBASE and CINAHL for published data on conservative surgical options (including radical trachelectomy) for FIGO IA2 squamous cervical cancer. It reports recurrence rates after radical trachelectomy of 0%–8% and notes over 35 live births among ≈210 women who underwent the operation, but also high rates of second-trimester pregnancy loss and preterm delivery; data on other conservative methods are limited. The authors conclude vaginal radical trachelectomy currently has the most data supporting its use as a fertility-sparing option but emphasize the lack of randomized (level I) evidence and recommend these techniques be performed by fully trained operators.
Reported effects: recurrence_rate_lower 0% · recurrence_rate_upper 8% · +1 more
Key findings
- Recurrence rates after radical trachelectomy range from 0% to 8% and are reported to be comparable to series of radical hysterectomy.
- There are over 35 reported live births out of approximately 210 women who had radical trachelectomy.
- Rates of second-trimester losses and preterm deliveries due to cervical weakness are high after trachelectomy.
- Data on other conservative methods are limited.
- There is a lack of level I evidence (randomized controlled trials) comparing conservative and radical methods; these procedures should be done by fully trained operators and are not the current standard treatment.
Limitations: Review/meta-analysis of published series rather than randomized trials: lack of level I evidence stated by authors.; Limited data available for other conservative methods besides radical trachelectomy.; Reproductive outcomes include high rates of second-trimester loss and preterm delivery.; Aggregated patient counts reported approximately ("approximately 210"), indicating some imprecision in sample size..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed